Literature DB >> 8060582

Cost effectiveness of 24-hour ambulatory blood pressure monitoring in evaluation and treatment of essential hypertension.

S A Yarows1, S Khoury, J R Sowers.   

Abstract

We wanted to determine if use of ambulatory blood pressure monitoring (ABPM) was cost effective, preventing unnecessary drug therapy in patients misdiagnosed as having essential hypertension, with elevated office blood pressures and normal ambulatory blood pressure. To address this issue we surveyed costs to the patient for antihypertensive drug therapy in 1990 of five local pharmacies in southeastern Michigan. Patients studied (n = 192) were seen in a private, general internal medicine practice in rural southeastern Michigan and received ABPM to assess the presence of hypertension and the adequacy of blood pressure treatment. We ascertained the average, minimal, and maximal drug cost to the patient per unit dose at the local pharmacies. The average yearly cost for patients on antihypertensive medications at pharmacies in southwestern Michigan was $578.40, with figures varying from $94.90 to $4361.75. Although there is no standard reimbursement amount for ABPM, at $188 per monitoring, the cost of monitoring this entire group of patients would offset exactly the cost of medication for the group of patients found to have only office hypertension. As such, third-party insurance carriers should consider reimbursement for ABPM in hypertension to decrease pharmaceutical cost and its attendant potential side effects. In conclusion, our study results suggest that ABPM is cost effective in an outpatient setting in preventing unwarranted drug therapy and the inappropriate diagnosis of hypertension.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8060582     DOI: 10.1093/ajh/7.5.464

Source DB:  PubMed          Journal:  Am J Hypertens        ISSN: 0895-7061            Impact factor:   2.689


  5 in total

1.  Intensified monitoring of circadian blood pressure and heart rate before and after intravitreous injection of bevacizumab: preliminary findings of a pilot study.

Authors:  Focke Ziemssen; Qi Zhu; Swaantje Peters; Salvatore Grisanti; Mohammed El Wardani; Peter Szurman; Karl U Bartz-Schmidt; Tjalf Ziemssen
Journal:  Int Ophthalmol       Date:  2008-04-17       Impact factor: 2.031

2.  Health Benefits and Cost-Effectiveness of Asymptomatic Screening for Hypertension and High Cholesterol and Aspirin Counseling for Primary Prevention.

Authors:  Steven P Dehmer; Michael V Maciosek; Amy B LaFrance; Thomas J Flottemesch
Journal:  Ann Fam Med       Date:  2017-01-06       Impact factor: 5.166

Review 3.  Clinical value of ambulatory blood pressure: Is it time to recommend for all patients with hypertension?

Authors:  Yalcin Solak; Kazuomi Kario; Adrian Covic; Nathan Bertelsen; Baris Afsar; Abdullah Ozkok; Andrzej Wiecek; Mehmet Kanbay
Journal:  Clin Exp Nephrol       Date:  2015-10-22       Impact factor: 2.801

4.  Is ambulatory blood pressure monitoring cost-effective in the routine surveillance of treated hypertensive patients in primary care?

Authors:  Paula Lorgelly; Ilias Siatis; Andrew Brooks; Barbara Slinn; Michael W Millar-Craig; Richard Donnelly; Gillian Manning
Journal:  Br J Gen Pract       Date:  2003-10       Impact factor: 5.386

Review 5.  Cost-effectiveness of secondary screening modalities for hypertension.

Authors:  Y Claire Wang; Alisa M Koval; Miyabi Nakamura; Jonathan D Newman; Joseph E Schwartz; Patricia W Stone
Journal:  Blood Press Monit       Date:  2013-02       Impact factor: 1.444

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.